A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

What are the side effects of Tirzepatide?

Reported side effects of Tirzepatide include: Nausea, Diarrhea, Vomiting, Constipation, Decreased appetite, Abdominal pain, Injection site reactions, Hypoglycemia (with insulin/sulfonylureas), Pancreatitis, Gallbladder problems, Acute kidney injury, BOXED WARNING: Thyroid C-cell tumors - contraindicated with MTC/MEN 2.

What is the typical dosing for Tirzepatide?

Prescribed doses per FDA labeling. Common doses observed in research: 2.5mg weekly (starting), 5mg weekly, 10mg weekly, 15mg weekly (max). Duration: Long-term / chronic use. Administration: Subcutaneous injection weekly.

Weight Loss

Tirzepatide

Also known as: Mounjaro, Zepbound, LY3298176

FDA Approved

Popular For

Weight loss, diabetes management, metabolic health

Key Facts: Tirzepatide

Category: Weight Loss
FDA Status: FDA Approved
Clinical Status: FDA Approved - Type 2 diabetes, chronic weight management, obstructive sleep apnea
Administration: Subcutaneous injection weekly
Typical Dose: 5-15 mg weekly (after titration)
Frequency: Once weekly
Evidence Level: FDA Approved
Duration: Long-term / chronic use

Also Known As

Mounjaro, Zepbound, LY3298176

Mechanism of Action

Tirzepatide activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. The dual mechanism enhances glucose-dependent insulin release while reducing glucagon and slowing gastric emptying.

Research Summary

SURMOUNT trials showed average weight loss of 20-26% body weight. SURMOUNT-OSA showed 25-29 fewer sleep apnea events per hour. SURPASS-2 showed superior A1C reduction compared to semaglutide. SUMMIT trial (2024-25) showed 38% reduction in CV death or worsening heart failure in HFpEF patients with obesity - data added to EU labeling Jan 2026.

Clinical Status:FDA Approved - Type 2 diabetes, chronic weight management, obstructive sleep apnea

Trial Progress:FDA Approved

Pre

III

FDA

FDA Approval Studies

This peptide is FDA approved. Below are the key clinical trials that supported its approval.

SURMOUNT Program (Tirzepatide for weight management)

Eli Lilly • Phase 3

Approved 2023

Participants:

5,000+ participants across SURMOUNT 1-4 trials

Duration:

72 weeks

Primary Endpoint:

Percent change in body weight from baseline

Key Results:

✓SURMOUNT-1: Up to 22.5% weight loss with 15mg dose
✓SURMOUNT-2 (with diabetes): Up to 15.7% weight loss
✓91% of participants achieved 5%+ weight loss
✓57% achieved 20%+ weight loss with highest dose

View Study

SURPASS Program (Tirzepatide for Type 2 Diabetes)

Eli Lilly • Phase 3

Approved 2022

Participants:

7,000+ participants across SURPASS 1-5 trials

Duration:

40-52 weeks

Primary Endpoint:

HbA1c reduction from baseline

Key Results:

✓Superior HbA1c reduction vs semaglutide (SURPASS-2)
✓Up to 2.46% HbA1c reduction from baseline
✓More patients reached HbA1c <7% vs comparators
✓Significant weight loss benefit alongside glycemic control

View Study

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

5-15 mg weekly (after titration)

Range

2.5-15 mg weekly

Frequency

Once weekly

Titrate up every 4 weeks. Start at 2.5 mg. Many find 10 mg effective for weight loss. GI side effects common during titration.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Prescribed doses per FDA labeling

Doses from Studies

2.5mg weekly (starting)

FDA Label - Mounjaro/Zepbound - Initial dose for all patients ↗

5mg weekly

SURMOUNT-1 Trial, NEJM 2022 - First maintenance tier - 15% avg weight loss ↗

10mg weekly

SURMOUNT-1 Trial, NEJM 2022 - Second maintenance tier - 19.5% avg weight loss ↗

15mg weekly (max)

SURMOUNT-1 Trial, NEJM 2022 - Maximum dose - 20.9% avg weight loss ↗

Duration

Long-term / chronic use

Administration

Subcutaneous injection weekly

Timing & Administration

Best Time to Take

Morning, same day each week

Once weekly, same day and time

Food Recommendation

With or without food

Why This Timing?

Weekly injection timing should be consistent. Morning dosing helps establish routine and monitor tolerance.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Nausea
●Diarrhea
●Vomiting
●Constipation
●Decreased appetite
●Abdominal pain
●Injection site reactions
●Hypoglycemia (with insulin/sulfonylureas)
●Pancreatitis
●Gallbladder problems
●Acute kidney injury
●BOXED WARNING: Thyroid C-cell tumors - contraindicated with MTC/MEN 2

References

Related Peptides

Peptides commonly compared with Tirzepatide or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Dulaglutide

FDA

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

Weight Loss

Exenatide

FDA

The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.

Weight Loss

Orforglipron

Clinical Trials

An oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.

Weight Loss

How to Use Tirzepatide Tirzepatide Alternatives Compare with Similar Browse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors

PRO

Want updates on Tirzepatide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides